{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T07:44:58Z","timestamp":1782719098918,"version":"3.54.5"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmogastro.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Gastrointestinal Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.esmogo.2026.100335","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:11:04Z","timestamp":1778253064000},"page":"100335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study"],"prefix":"10.1016","volume":"12","author":[{"given":"H.","family":"Vandeputte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Casadei-Gardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rimini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Nichetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4857-4276","authenticated-orcid":false,"given":"A.","family":"Saborowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7885-0636","authenticated-orcid":false,"given":"L.","family":"Passeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Satake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Vivaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6919-1536","authenticated-orcid":false,"given":"T.","family":"Pressiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0262-535X","authenticated-orcid":false,"given":"J.","family":"Lucchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.W.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5666-6085","authenticated-orcid":false,"given":"O.","family":"Abidoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6672-0233","authenticated-orcid":false,"given":"S.","family":"Corallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1802-5671","authenticated-orcid":false,"given":"I.G.","family":"Rapposelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tamberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8559-9910","authenticated-orcid":false,"given":"F.","family":"Finkelmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pircher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6979-5812","authenticated-orcid":false,"given":"H.J.","family":"Chon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Braconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Qaisar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8160-9769","authenticated-orcid":false,"given":"C.","family":"Pirrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5416-5383","authenticated-orcid":false,"given":"F.","family":"Castet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4619-7091","authenticated-orcid":false,"given":"E.","family":"Tamburini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2900-5640","authenticated-orcid":false,"given":"A.","family":"Lancianese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Diana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Scartozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.W.","family":"Prager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Avallone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schirripa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0484-0974","authenticated-orcid":false,"given":"L.","family":"Perkhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7861-7882","authenticated-orcid":false,"given":"E.","family":"Oneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Verrico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9553-3189","authenticated-orcid":false,"given":"N.","family":"Couto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3959-4120","authenticated-orcid":false,"given":"J.","family":"Adeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8998-5480","authenticated-orcid":false,"given":"S.L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4363-6274","authenticated-orcid":false,"given":"G.P.","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7995-272X","authenticated-orcid":false,"given":"N.","family":"Personeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Garajova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3163-7982","authenticated-orcid":false,"given":"M.G.","family":"Rodriquenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.M.","family":"Alvim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7507-2506","authenticated-orcid":false,"given":"R.","family":"Roque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3659-4800","authenticated-orcid":false,"given":"G.","family":"Farinea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Lanzetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4368-6973","authenticated-orcid":false,"given":"R.","family":"Balsano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Lavacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8203-1684","authenticated-orcid":false,"given":"S.","family":"Camera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4050-2086","authenticated-orcid":false,"given":"M.","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Niger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Tesini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Tonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6491-2277","authenticated-orcid":false,"given":"M.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Bekaii-Saab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1680-2952","authenticated-orcid":false,"given":"L.","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7242-4396","authenticated-orcid":false,"given":"A.","family":"Boccaccino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3142-483X","authenticated-orcid":false,"given":"M.","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Lo Prinzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Himmelsbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Landriscina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.A.","family":"Djaballah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Persano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7749-8634","authenticated-orcid":false,"given":"F.","family":"Salani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Fornaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9957-3615","authenticated-orcid":false,"given":"L.","family":"Rimassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7208-3480","authenticated-orcid":false,"given":"J.","family":"Dekervel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmogo.2026.100335_bib1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41575-025-01153-w","article-title":"Cholangiocarcinoma 2026: status quo, unmet needs and priorities","volume":"23","author":"Banales","year":"2026","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.esmogo.2026.100335_bib2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.32074\/1591-951X-252","article-title":"Cholangiocarcinoma","volume":"113","author":"Sarcognato","year":"2021","journal-title":"Pathologica"},{"key":"10.1016\/j.esmogo.2026.100335_bib3","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.jhep.2022.07.022","article-title":"Current epidemiology of cholangiocarcinoma in Western countries","volume":"77","author":"Vithayathil","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.esmogo.2026.100335_bib4","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.esmogo.2026.100335_bib5","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evidence"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100335_bib6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.esmogo.2026.100335_bib7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmogo.2026.100335_bib8","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1053\/j.gastro.2013.10.013","article-title":"Pathogenesis, diagnosis, and management of cholangiocarcinoma","volume":"145","author":"Ilyas","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.esmogo.2026.100335_bib9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","article-title":"Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)","volume":"13","author":"Banales","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.esmogo.2026.100335_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114199","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: a large real-life worldwide population","volume":"208","author":"Rimini","year":"2024","journal-title":"Eur J Cancer"},{"issue":"10391","key":"10.1016\/j.esmogo.2026.100335_bib11","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100335_bib12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/bjc.2011.189","article-title":"The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis","volume":"105","author":"Gooden","year":"2011","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.esmogo.2026.100335_bib13","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/pcmr.13109","article-title":"Neutrophil-to-eosinophil ratio as a biomarker for clinical outcomes in advanced-stage melanoma patients treated with anti-PD-1 therapy","volume":"36","author":"Pozorski","year":"2023","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.esmogo.2026.100335_bib14","doi-asserted-by":"crossref","first-page":"658","DOI":"10.2340\/1651-226X.2024.40390","article-title":"Baseline neutrophil-to-eosinophil-ratio and outcome in metastatic clear-cell renal cell carcinoma treated with nivolumab or ipilimumab\/nivolumab","volume":"63","author":"Beulque","year":"2024","journal-title":"Acta Oncol"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100335_bib15","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41598-024-84890-3","article-title":"Pretreatment neutrophil-to-lymphocyte ratio is associated with immunotherapy efficacy in patients with advanced cancer: a systematic review and meta-analysis","volume":"15","author":"Su","year":"2025","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100335_bib16","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1186\/s12967-023-04418-7","article-title":"Eosinophils in the tumor microenvironment: implications for cancer immunotherapy","volume":"21","author":"Ghaffari","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.esmogo.2026.100335_bib17","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ccell.2022.11.014","article-title":"IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer","volume":"41","author":"Blomberg","year":"2023","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.esmogo.2026.100335_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.esmogo.2026.100335_bib19","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.16291","article-title":"Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis","volume":"8","author":"Bowen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmogo.2026.100335_bib20","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.21037\/jtd.2019.07.30","article-title":"Neutrophil-to-lymphocyte ratio as prognostic marker in esophageal cancer: a systematic review and meta-analysis","volume":"11","author":"Pirozzolo","year":"2019","journal-title":"J Thorac Dis"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100335_bib21","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1186\/s12885-018-5131-x","article-title":"New pre-treatment eosinophil-related ratios as prognostic biomarkers for survival outcomes in endometrial cancer","volume":"18","author":"Holub","year":"2018","journal-title":"BMC Cancer"},{"issue":"21","key":"10.1016\/j.esmogo.2026.100335_bib22","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.3390\/cancers16213689","article-title":"Prognostic value of neutrophil-to-eosinophil ratio (NER) in cancer: a systematic review and meta-analysis","volume":"16","author":"Sahin","year":"2024","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100335_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00262-008-0516-3","article-title":"Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment","volume":"58","author":"Cho","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.esmogo.2026.100335_bib24","first-page":"1","article-title":"Development of a predictive model utilizing the neutrophil to lymphocyte ratio to predict neoadjuvant chemotherapy efficacy in early breast cancer patients","volume":"11","author":"Zhu","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.esmogo.2026.100335_bib25","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.4130","article-title":"Neutrophil\/lymphocyte ratio (NLR) as a prognostic factor in biliary tract cancer (BTC)","volume":"31","author":"McNamara","year":"2013","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmogo.2026.100335_bib26","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.hpb.2016.08.006","article-title":"Elevated NLR in gallbladder cancer and cholangiocarcinoma\u2014making bad cancers even worse: results from the US Extrahepatic Biliary Malignancy Consortium","volume":"18","author":"Beal","year":"2016","journal-title":"HPB"},{"key":"10.1016\/j.esmogo.2026.100335_bib27","article-title":"Prognostic significance of neutrophil-to-lymphocyte ratio in biliary tract cancers: a systematic review and meta-analysis","volume":"8","author":"Tang","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.esmogo.2026.100335_bib28","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.esmogo.2026.100335_bib29","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/MPA.0000000000001731","article-title":"The prognostic impact of eosinophils and the eosinophil-to-lymphocyte ratio on survival outcomes in stage II resectable pancreatic cancer","volume":"50","author":"Ohkuma","year":"2021","journal-title":"Pancreas"},{"key":"10.1016\/j.esmogo.2026.100335_bib30","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s12199-016-0530-6","article-title":"Prognostic value of the lymphocyte-to-monocyte ratio and other inflammatory markers in malignant pleural mesothelioma","volume":"21","author":"Tanrikulu","year":"2016","journal-title":"Environ Health Prev Med"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100335_bib31","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1186\/s12885-018-5042-x","article-title":"Neutrophils to lymphocytes ratio as a useful prognosticator for stage II colorectal cancer patients","volume":"18","author":"Dimitriou","year":"2018","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.esmogo.2026.100335_bib32","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00262-018-2126-z","article-title":"Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis","volume":"67","author":"Jiang","year":"2018","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10.1016\/j.esmogo.2026.100335_bib33","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.mehy.2007.06.017","article-title":"Eosinophil-induced prognosis improvement of solid tumors could be enabled by their vesicle-mediated barrier permeability induction","volume":"70","author":"Mingomataj","year":"2008","journal-title":"Med Hypotheses"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100335_bib34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.anai.2014.04.002","article-title":"Changing roles of eosinophils in health and disease","volume":"113","author":"Furuta","year":"2014","journal-title":"Ann Allergy, Asthma and Immunology"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100335_bib35","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1600-065X.2011.01026.x","article-title":"Eosinophils: multifaceted biological properties and roles in health and disease","volume":"242","author":"Kita","year":"2011","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100335_bib36","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00441-010-1049-6","article-title":"Eosinophils in innate immunity: an evolving story","volume":"343","author":"Shamri","year":"2011","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.esmogo.2026.100335_bib37","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0065-2776(08)60351-X","article-title":"The eosinophilic leukocyte: structure and function","volume":"39","author":"Gleich","year":"1986","journal-title":"Adv Immunol"},{"key":"10.1016\/j.esmogo.2026.100335_bib38","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000445215","article-title":"A player and coordinator: the versatile roles of eosinophils in the immune system","volume":"43","author":"Long","year":"2016","journal-title":"Transfus Med Hemother"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100335_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/2326-6066.CIR-13-0196","article-title":"Eosinophils and cancer","volume":"2","author":"Davis","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"10.1016\/j.esmogo.2026.100335_bib40","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2217\/imt-2016-0138","article-title":"Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy","volume":"9","author":"Moreira","year":"2017","journal-title":"Immunotherapy"},{"issue":"5","key":"10.1016\/j.esmogo.2026.100335_bib41","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1111\/ajco.12871","article-title":"The impacts of pretreatment circulating eosinophils and basophils on prognosis of stage I-III colorectal cancer","volume":"14","author":"Wei","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmogo.2026.100335_bib42","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.3390\/ijms25052929","article-title":"Neutrophils at the crossroads: unraveling the multifaceted role in the tumor microenvironment","volume":"25","author":"Awasthi","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.esmogo.2026.100335_bib43","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2147\/OTT.S153290","article-title":"Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis","volume":"11","author":"Sacdalan","year":"2018","journal-title":"Onco Targets Ther"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100335_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-20935-9","article-title":"Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors","volume":"12","author":"Valero","year":"2021","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.esmogo.2026.100335_bib45","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.21873\/anticanres.15781","article-title":"Neutrophil-to-lymphocyte ratio to predict the efficacy of immune checkpoint inhibitor in upper gastrointestinal cancer","volume":"42","author":"Booka","year":"2022","journal-title":"Anticancer Res"},{"key":"10.1016\/j.esmogo.2026.100335_bib46","article-title":"Neutrophil-to-lymphocyte ratio as a prognostic biomarker for patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"11","author":"Chen","year":"2011","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.esmogo.2026.100335_bib47","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cllc.2018.12.003","article-title":"Perspectives: neutrophil-to-lymphocyte ratio as a potential biomarker in immune checkpoint inhibitor for non\u2013small-cell lung cancer","volume":"20","author":"Park","year":"2019","journal-title":"Clin Lung Cancer"},{"issue":"6","key":"10.1016\/j.esmogo.2026.100335_bib48","doi-asserted-by":"crossref","first-page":"602.e1","DOI":"10.1016\/j.urolonc.2020.02.005","article-title":"The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients","volume":"38","author":"Ogihara","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.esmogo.2026.100335_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/10732748241285474","article-title":"Predictability of neutrophile to lymphocyte ratio and platelet to lymphocyte ratio on the effectiveness of immune checkpoint inhibitors in non-small cell lung cancer patients: a meta-analysis","volume":"31","author":"Nguyen","year":"2024","journal-title":"Cancer Control"},{"issue":"15","key":"10.1016\/j.esmogo.2026.100335_bib50","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1111\/1759-7714.14063","article-title":"Association between pretreatment neutrophil-to-lymphocyte ratio and immune-related adverse events due to immune checkpoint inhibitors in patients with non-small cell lung cancer","volume":"12","author":"Fujimoto","year":"2021","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.esmogo.2026.100335_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1483956","article-title":"Eosinophil is a predictor of severe immune-related adverse events induced by ipilimumab plus nivolumab therapy in patients with renal cell carcinoma: a retrospective multicenter cohort study","volume":"15","author":"Tasaki","year":"2025","journal-title":"Front Immunol"}],"container-title":["ESMO Gastrointestinal Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S294981982600035X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S294981982600035X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T06:52:58Z","timestamp":1782715978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S294981982600035X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":51,"alternative-id":["S294981982600035X"],"URL":"https:\/\/doi.org\/10.1016\/j.esmogo.2026.100335","relation":{},"ISSN":["2949-8198"],"issn-type":[{"value":"2949-8198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"ESMO Gastrointestinal Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmogo.2026.100335","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100335"}}